Heidelberg Pharma Amends Royalty Agreement With HealthCare Royalty, Adds Soleus Capital Financing

Heidelberg Pharma AG announced an amendment to its existing royalty purchase agreement with HealthCare Royalty and the participation of Soleus Capital Management to partially monetize future royalties from the imaging diagnostic agent TLX250-Px. Under the revised arrangement, Soleus Capital will provide an upfront payment of USD 20 million to Heidelberg Pharma, subject to closing conditions, and an additional USD 25 million upon U.S. FDA approval of TLX250-Px. Payments from HealthCare Royalty under the existing agreement remain unchanged.

New Financing Strengthens Development Runway

The amended agreement enables Heidelberg Pharma to secure non-dilutive financing tied to future royalties from worldwide sales of TLX250-Px, a diagnostic imaging agent developed by Telix Pharmaceuticals Limited. The upfront funding and potential milestone payment from Soleus Capital are expected to strengthen the company’s financial position and support continued development of its antibody–drug conjugate pipeline.

Strategic Royalty Monetization for Biotech Funding

The transaction builds on the original 2024 royalty sale agreement between Heidelberg Pharma and HealthCare Royalty, which allowed the company to monetize a portion of its future royalty stream. The latest amendment also increases the cap on total payments and ensures the company’s financing outlook extends to mid-2027, highlighting the growing role of royalty-based financing in supporting biotech innovation.